CD274 and non-small cell lung carcinoma: For example, with respect to the second or subsequent line treatment for metastatic NSCLC, where the maximum activity of the chemotherapy is around 10–15%, the identification of a predictive biomarker able to improve ORR over 20% in the PD-L1 positive tumor should be considered clinically meaningful [11].